^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MYD88 mutation

    i
    Other names: MYD88, MYD88 Innate Immune Signal Transduction Adaptor, Myeloid Differentiation Primary Response Protein MyD88, Myeloid Differentiation Primary Response Gene (88), Myeloid Differentiation Primary Response 88, Mutant Myeloid Differentiation Primary Response 88, MYD88D
    Entrez ID:
    4615
    Related biomarkers:
    Expression
    Mutation
    Others
    11ms
    A Rare Case of Chronic Lymphocytic Leukemia Transforming Into Waldenström Macroglobulinemia During Ibrutinib Therapy. (PubMed, Cureus)
    Symptoms arise from tumor infiltration and monoclonal protein production. Here, we present a case of CLL transforming into WM during treatment with ibrutinib. Given the rarity of such a transformation, this case may serve as a valuable reference, and further investigation is needed to understand the pathology underlying this transformation.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • SDC1 (Syndecan 1)
    |
    MYD88 mutation
    |
    Imbruvica (ibrutinib)
    12ms
    Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS). (PubMed, Cancer Med)
    In conclusion, we uncovered new insights into the mutational landscape of WM, depicting a more complex involvement of the NF-kB pathway, and providing evidence of the recurrence of some variants (MYD88, IL17RB, NFKB2, ATM, CARD11, PTPN13, and WNK2) also in IgM MGUS.
    Journal
    |
    ARID1A (AT-rich interaction domain 1A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • KMT2C (Lysine Methyltransferase 2C) • CARD11 (Caspase Recruitment Domain Family Member 11) • SDC1 (Syndecan 1) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • WNK2 (WNK Lysine Deficient Protein Kinase 2) • IL17RB (Interleukin 17 Receptor B)
    |
    ARID1A mutation • MYD88 mutation • MYD88 L265P
    12ms
    Lymphoplasmacytic lymphoma and Waldenström Macroglobulinemia, A Decade After the Discovery of MYD88L265P. (PubMed, Hum Pathol)
    Key concepts in the diagnosis and their clinical implications are emphasized. Controversies and challenges are also discussed.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    MYD88 mutation • MYD88 L265P
    1year
    Expression of MYD88 L265P Mutation in Subtypes of Diffuse Large B-Cell Lymphoma in the Pakistani Population. (PubMed, Appl Immunohistochem Mol Morphol)
    This association will assist in identifying a target population that may benefit from MYD88-specific treatment regimens. This may exponentially improve the outcome of patients with DLBCL harboring this mutation.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    MYD88 mutation • MYD88 L265P
    1year
    Peripheral Neuropathy in the Phase 3 ASPEN Study of Bruton Tyrosine Kinase Inhibitors for Waldenström Macroglobulinemia. (PubMed, Blood Adv)
    The phase 3 ASPEN study compared the efficacy and safety of zanubrutinib with ibrutinib in patients with WM. While further investigation is required, this analysis supports the potential use and further exploration of Bruton tyrosine kinase inhibitors to treat PN symptoms in patients with WM. ClinicalTrials.gov: NCT03053440.
    P3 data • Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    MYD88 mutation
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib)
    1year
    A rare case of splenic marginal zone lymphoma with MYD88 mutation transformed into diffuse large B-cell lymphoma: case report and literature review. (PubMed, Ann Hematol)
    Through this case, we reviewed relevant studies, which indicated that MYD88 mutations, along with other genetic anomalies, may play a significant role in this process. In the future, it is essential to collect more of these rare cases for further research.
    Review • Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    MYD88 mutation
    1year
    High Prevalence of MYD88 and CD79B Mutations in Primary Sinonasal Diffuse Large B-Cell Lymphoma: Identification of an MCD-like Subtype. (PubMed, Am J Surg Pathol)
    In conclusion, our study highlights a high prevalence of MYD88 and CD79B mutations in PSDLBCL, identifying an aggressive MCD-like subtype with a distinct relapse pattern. This molecular subclassification can be helpful for both prognostic prediction and therapeutic strategy in patients with PSDLBCL.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • CD79B (CD79b Molecule)
    |
    MYD88 mutation • MYD88 L265P • CD79B mutation • CD79B mutation • BCL6 translocation • BCL2 translocation
    1year
    Clinicopathological and genetic analyses of thyroid large B-cell lymphoma in a Japanese population. (PubMed, J Clin Exp Hematop)
    Even MYC-R cases showed better prognosis. Further studies involving a large series of LBCLs in extranodal organs are needed to expand on the findings of this study.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • MALT1 (MALT1 Paracaspase)
    |
    MYD88 mutation
    1year
    Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients. (PubMed, J Egypt Natl Canc Inst)
    Our findings indicate a high frequency of MYD88 L265P mutations in our study population and not associated with prognostic markers or the outcome of the disease.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    MYD88 mutation • MYD88 L265P
    1year
    Determination of MYD88 and CXCR4 mutation for clinical detection and their significance in Waldenström macroglobulinemia. (PubMed, Clin Cancer Res)
    Testing for MYD88 mutations using AS-PCR or ddPCR in unsorted samples is viable for routine clinical practice. Under BTKi treatment, MYD88 and CXCR4 mutations hold greater prognostic importance than IPSSWM staging in WM.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    MYD88 mutation • CXCR4 mutation • MYD88 mutation + CXCR4 mutation
    |
    Rituxan (rituximab) • bortezomib
    1year
    Next-generation integrated sequencing identifies poor prognostic factors in patients with MYD88-mutated chronic lymphocytic leukemia in Taiwan. (PubMed, Pathobiology)
    IGLL5, MYD88, and KMT2D mutations were enriched in Taiwanese CLL, and co-occurrence of MYD88 mutations with KMT2D or/and IGLL5 mutations was associated with a poorer prognosis.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IGH (Immunoglobulin Heavy Locus) • KMT2D (Lysine Methyltransferase 2D) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5) • DSCAM (DS Cell Adhesion Molecule) • TCHH (Trichohyalin)
    |
    MYD88 mutation • KMT2D mutation • MYD88 L265P • IGLL5 mutation